- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06549595
En studie av AZD0486 Plus Rituximab hos tidligere ubehandlede follikulært lymfompasienter
En fase III, multisenter, randomisert, åpen studie for å sammenligne effektiviteten og sikkerheten til AZD0486 Plus Rituximab versus Kjemoterapi Plus Rituximab hos tidligere ubehandlede deltakere med follikulært lymfom
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The study consists of 2 sequential parts.
-
Safety Run-in - this part will compare dose levels of Surovatamig (AZD0486) in combination with rituximab in order to establish the RP3D.
-
Phase III - The Phase III part will assess the superiority of Surovatamig (AZD0486) at RP3D in combination with rituximab, compared to Investigator's choice between 3 standard chemoimmunotherapy regimens. Phase 3 consists of 3 arms
- Arm A: treatment with Surovatamig plus rituximab Schedule A
- Arm B: treatment with Surovatamig plus rituximab Schedule B
- Arm C (Comparator arm): one of the following standard regimens per Investigator's choice: R-CVP + rituximab maintenance, R-CHOP + rituximab maintenance or B-R + rituximab maintenance
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-post: information.center@astrazeneca.com
Studiesteder
-
-
-
Clayton, Australia, 3168
- Har ikke rekruttert ennå
- Research Site
-
Darlinghurst, Australia, 2010
- Rekruttering
- Research Site
-
Garran, Australia, 2605
- Rekruttering
- Research Site
-
Heidelberg, Australia, 3084
- Rekruttering
- Research Site
-
Macquarie University, Australia, 2109
- Rekruttering
- Research Site
-
Nedlands, Australia, 6009
- Rekruttering
- Research Site
-
-
-
-
-
Brussels, Belgia, 1070
- Har ikke rekruttert ennå
- Research Site
-
Brussels, Belgia, 1090
- Har ikke rekruttert ennå
- Research Site
-
Ghent, Belgia, 9000
- Har ikke rekruttert ennå
- Research Site
-
Mechelen, Belgia, 2800
- Har ikke rekruttert ennå
- Research Site
-
-
-
-
-
Porto Alegre, Brasil, 90035-003
- Rekruttering
- Research Site
-
São Paulo, Brasil, 04501-000
- Rekruttering
- Research Site
-
São Paulo, Brasil, 05652-900
- Rekruttering
- Research Site
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- Rekruttering
- Research Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Rekruttering
- Research Site
-
-
Ontario
-
Barrie, Ontario, Canada, L4M 6M2
- Tilbaketrukket
- Research Site
-
Hamilton, Ontario, Canada, L8V 5C2
- Rekruttering
- Research Site
-
Oshawa, Ontario, Canada, L1G 2B9
- Rekruttering
- Research Site
-
Toronto, Ontario, Canada, M5G 1X6
- Rekruttering
- Research Site
-
-
Quebec
-
Chicoutimi, Quebec, Canada, G7H 5H6
- Rekruttering
- Research Site
-
Montreal, Quebec, Canada, H4J 1C5
- Rekruttering
- Research Site
-
Québec, Quebec, Canada, G1J 1Z4
- Rekruttering
- Research Site
-
Saint-Jérôme, Quebec, Canada, J7Z 2V4
- Rekruttering
- Research Site
-
-
-
-
-
Aalborg, Danmark, 9100
- Tilbaketrukket
- Research Site
-
Copenhagen, Danmark, 2100
- Rekruttering
- Research Site
-
Odense C, Danmark, 5000
- Rekruttering
- Research Site
-
Roskilde, Danmark, 4000
- Tilbaketrukket
- Research Site
-
-
-
-
-
Helsinki, Finland, 00029
- Tilbaketrukket
- Research Site
-
Kuopio, Finland, 70029
- Tilbaketrukket
- Research Site
-
Tampere, Finland, 33520
- Tilbaketrukket
- Research Site
-
-
-
-
Alabama
-
Huntsville, Alabama, Forente stater, 35805
- Rekruttering
- Research Site
-
-
Alaska
-
Anchorage, Alaska, Forente stater, 99508
- Rekruttering
- Research Site
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85054
- Rekruttering
- Research Site
-
-
California
-
Clovis, California, Forente stater, 93611
- Har ikke rekruttert ennå
- Research Site
-
Los Alamitos, California, Forente stater, 90720
- Rekruttering
- Research Site
-
San Diego, California, Forente stater, 92121
- Har ikke rekruttert ennå
- Research Site
-
Santa Monica, California, Forente stater, 90404
- Har ikke rekruttert ennå
- Research Site
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Tilbaketrukket
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06510
- Rekruttering
- Research Site
-
-
Delaware
-
Newark, Delaware, Forente stater, 19713
- Har ikke rekruttert ennå
- Research Site
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32224
- Rekruttering
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Har ikke rekruttert ennå
- Research Site
-
Macon, Georgia, Forente stater, 31201
- Rekruttering
- Research Site
-
-
Illinois
-
Evanston, Illinois, Forente stater, 60201
- Har ikke rekruttert ennå
- Research Site
-
Peoria, Illinois, Forente stater, 61615
- Har ikke rekruttert ennå
- Research Site
-
-
Indiana
-
Fort Wayne, Indiana, Forente stater, 46804
- Rekruttering
- Research Site
-
-
Iowa
-
Des Moines, Iowa, Forente stater, 50309
- Har ikke rekruttert ennå
- Research Site
-
Iowa City, Iowa, Forente stater, 52242
- Har ikke rekruttert ennå
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40536
- Har ikke rekruttert ennå
- Research Site
-
Louisville, Kentucky, Forente stater, 40207
- Har ikke rekruttert ennå
- Research Site
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70808
- Har ikke rekruttert ennå
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21201
- Har ikke rekruttert ennå
- Research Site
-
Bethesda, Maryland, Forente stater, 20817
- Rekruttering
- Research Site
-
Columbia, Maryland, Forente stater, 21044
- Har ikke rekruttert ennå
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Har ikke rekruttert ennå
- Research Site
-
Boston, Massachusetts, Forente stater, 02215
- Har ikke rekruttert ennå
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Har ikke rekruttert ennå
- Research Site
-
Detroit, Michigan, Forente stater, 48201
- Tilbaketrukket
- Research Site
-
Ypsilanti, Michigan, Forente stater, 48197
- Har ikke rekruttert ennå
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Rekruttering
- Research Site
-
Saint Paul, Minnesota, Forente stater, 55102
- Har ikke rekruttert ennå
- Research Site
-
-
Missouri
-
Chesterfield, Missouri, Forente stater, 63017
- Har ikke rekruttert ennå
- Research Site
-
Springfield, Missouri, Forente stater, 65807
- Rekruttering
- Research Site
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601
- Har ikke rekruttert ennå
- Research Site
-
New Brunswick, New Jersey, Forente stater, 08901
- Har ikke rekruttert ennå
- Research Site
-
-
New York
-
Albany, New York, Forente stater, 12206
- Rekruttering
- Research Site
-
Brooklyn, New York, Forente stater, 11220
- Har ikke rekruttert ennå
- Research Site
-
Mineola, New York, Forente stater, 11501
- Har ikke rekruttert ennå
- Research Site
-
New Hyde Park, New York, Forente stater, 11042
- Har ikke rekruttert ennå
- Research Site
-
New York, New York, Forente stater, 10065
- Rekruttering
- Research Site
-
New York, New York, Forente stater, 10032
- Rekruttering
- Research Site
-
New York, New York, Forente stater, 10016
- Rekruttering
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28204
- Rekruttering
- Research Site
-
Charlotte, North Carolina, Forente stater, 28204
- Har ikke rekruttert ennå
- Research Site
-
Wilmington, North Carolina, Forente stater, 28401
- Har ikke rekruttert ennå
- Research Site
-
Winston-Salem, North Carolina, Forente stater, 27103
- Har ikke rekruttert ennå
- Research Site
-
-
Ohio
-
Blue Ash, Ohio, Forente stater, 45242
- Har ikke rekruttert ennå
- Research Site
-
Cincinnati, Ohio, Forente stater, 45219
- Har ikke rekruttert ennå
- Research Site
-
Columbus, Ohio, Forente stater, 43210
- Har ikke rekruttert ennå
- Research Site
-
-
Oregon
-
Eugene, Oregon, Forente stater, 97401
- Har ikke rekruttert ennå
- Research Site
-
Portland, Oregon, Forente stater, 97227
- Tilbaketrukket
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15232
- Har ikke rekruttert ennå
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Research Site
-
-
Texas
-
Austin, Texas, Forente stater, 78705
- Har ikke rekruttert ennå
- Research Site
-
Lubbock, Texas, Forente stater, 79430
- Har ikke rekruttert ennå
- Research Site
-
Shenandoah, Texas, Forente stater, 77380
- Har ikke rekruttert ennå
- Research Site
-
Tyler, Texas, Forente stater, 75702
- Har ikke rekruttert ennå
- Research Site
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84112
- Har ikke rekruttert ennå
- Research Site
-
-
Virginia
-
Fairfax, Virginia, Forente stater, 22031
- Har ikke rekruttert ennå
- Research Site
-
Richmond, Virginia, Forente stater, 23219
- Har ikke rekruttert ennå
- Research Site
-
-
Washington
-
Tacoma, Washington, Forente stater, 98405
- Rekruttering
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53792
- Har ikke rekruttert ennå
- Research Site
-
Milwaukee, Wisconsin, Forente stater, 53226
- Har ikke rekruttert ennå
- Research Site
-
-
-
-
-
Bayonne, Frankrike, 64100
- Har ikke rekruttert ennå
- Research Site
-
La Tronche, Frankrike, 38700
- Tilbaketrukket
- Research Site
-
Lille, Frankrike, 59037
- Har ikke rekruttert ennå
- Research Site
-
Montpellier, Frankrike, 34295
- Har ikke rekruttert ennå
- Research Site
-
Saint-Cloud, Frankrike, 92210
- Har ikke rekruttert ennå
- Research Site
-
Vandœuvre-lès-Nancy, Frankrike, 54511
- Tilbaketrukket
- Research Site
-
-
-
-
-
Hong Kong, Hong Kong, 999077
- Rekruttering
- Research Site
-
-
-
-
-
Delhi, India, 110029
- Har ikke rekruttert ennå
- Research Site
-
Delhi, India, 110085
- Rekruttering
- Research Site
-
Gurugram, India, 122002
- Har ikke rekruttert ennå
- Research Site
-
Kolkata, India, 700160
- Rekruttering
- Research Site
-
Nashik, India, 422002
- Rekruttering
- Research Site
-
Surat, India, 396007
- Rekruttering
- Research Site
-
Thiruvananthapuram, India, 695011
- Rekruttering
- Research Site
-
-
-
-
-
Bologna, Italia, 40138
- Har ikke rekruttert ennå
- Research Site
-
Milan, Italia, 20141
- Har ikke rekruttert ennå
- Research Site
-
Reggio Emilia, Italia, 42100
- Har ikke rekruttert ennå
- Research Site
-
-
-
-
-
Bunkyō City, Japan, 113-8677
- Rekruttering
- Research Site
-
Chiba, Japan, 260-8717
- Rekruttering
- Research Site
-
Chuo-shi, Japan, 409-3898
- Rekruttering
- Research Site
-
Fukuoka, Japan, 812-8582
- Rekruttering
- Research Site
-
Hirakata-shi, Japan, 573-1191
- Rekruttering
- Research Site
-
Kobe, Japan, 650-0047
- Rekruttering
- Research Site
-
Kumamoto, Japan, 860-8556
- Rekruttering
- Research Site
-
Kurashiki-shi, Japan, 710-8602
- Rekruttering
- Research Site
-
Kyoto, Japan, 602-8566
- Rekruttering
- Research Site
-
Kōtoku, Japan, 135-8550
- Rekruttering
- Research Site
-
Minatoku, Japan, 105-8470
- Rekruttering
- Research Site
-
Okayama, Japan, 700-8558
- Rekruttering
- Research Site
-
Osaka, Japan, 541-8567
- Rekruttering
- Research Site
-
Sapporo, Japan, 060-8638
- Rekruttering
- Research Site
-
Sapporo, Japan, 003-0006
- Rekruttering
- Research Site
-
Sunto-gun, Japan, 411-8777
- Rekruttering
- Research Site
-
Toyoake-shi, Japan, 470-1192
- Rekruttering
- Research Site
-
Yamagata, Japan, 990-9585
- Rekruttering
- Research Site
-
Yokohama, Japan, 241-8515
- Rekruttering
- Research Site
-
-
-
-
-
Beijing, Kina, 100730
- Rekruttering
- Research Site
-
Beijing, Kina, 100044
- Rekruttering
- Research Site
-
Beijing, Kina, 100142
- Rekruttering
- Research Site
-
Changchun, Kina, 130021
- Rekruttering
- Research Site
-
Changsha, Kina, 410013
- Rekruttering
- Research Site
-
Chengdu, Kina, 610078
- Rekruttering
- Research Site
-
Chongqing, Kina, 400030
- Rekruttering
- Research Site
-
Fuzhou, Kina, 350001
- Rekruttering
- Research Site
-
Guangzhou, Kina, 510060
- Rekruttering
- Research Site
-
Guangzhou, Kina, 510100
- Rekruttering
- Research Site
-
Guangzhou, Kina, 510000
- Rekruttering
- Research Site
-
Hangzhou, Kina, 310022
- Har ikke rekruttert ennå
- Research Site
-
Hangzhou, Kina, 310003
- Rekruttering
- Research Site
-
Harbin, Kina, 150081
- Rekruttering
- Research Site
-
Hefei, Kina, 230031
- Rekruttering
- Research Site
-
Lanzhou, Kina, 730000
- Rekruttering
- Research Site
-
Nanchang, Kina, 330006
- Rekruttering
- Research Site
-
Nanchang, Kina, 330029
- Rekruttering
- Research Site
-
Nanjing, Kina, 210029
- Rekruttering
- Research Site
-
Nanning, Kina, 530021
- Rekruttering
- Research Site
-
Shandong, Kina, 250117
- Rekruttering
- Research Site
-
Shanghai, Kina, 200065
- Rekruttering
- Research Site
-
Shanghai, Kina, 20032
- Rekruttering
- Research Site
-
Shenyang, Kina, 110001
- Rekruttering
- Research Site
-
Shenyang, Kina, 110004
- Rekruttering
- Research Site
-
Shijiazhuang, Kina, 054001
- Rekruttering
- Research Site
-
Suzhou, Kina, 215006
- Rekruttering
- Research Site
-
Tianjin, Kina, 300020
- Rekruttering
- Research Site
-
Wenzhou, Kina, 325000
- Rekruttering
- Research Site
-
Wuhan, Kina, 430079
- Rekruttering
- Research Site
-
Xi'an, Kina, 710114
- Rekruttering
- Research Site
-
Xiamen, Kina, 361003
- Rekruttering
- Research Site
-
Zhengzhou, Kina, 450000
- Rekruttering
- Research Site
-
Zhengzhou, Kina, 450008
- Rekruttering
- Research Site
-
-
-
-
-
Gdansk, Polen, 80-214
- Har ikke rekruttert ennå
- Research Site
-
Gliwice, Polen, 44-102
- Tilbaketrukket
- Research Site
-
Katowice, Polen, 40-519
- Har ikke rekruttert ennå
- Research Site
-
Krakow, Polen, 30-727
- Har ikke rekruttert ennå
- Research Site
-
Lublin, Polen, 20-081
- Tilbaketrukket
- Research Site
-
Lublin, Polen, 20-090
- Suspendert
- Research Site
-
Warsaw, Polen, 02-781
- Har ikke rekruttert ennå
- Research Site
-
Wroclaw, Polen, 50-019
- Har ikke rekruttert ennå
- Research Site
-
Wroclaw, Polen, 53-439
- Tilbaketrukket
- Research Site
-
-
-
-
-
San Juan, Puerto Rico, 00918
- Rekruttering
- Research Site
-
-
-
-
-
Barcelona, Spania, 08035
- Har ikke rekruttert ennå
- Research Site
-
Barcelona, Spania, 8036
- Tilbaketrukket
- Research Site
-
El Palmar, Spania, 30120
- Tilbaketrukket
- Research Site
-
Girona, Spania, 17007
- Har ikke rekruttert ennå
- Research Site
-
Las Palmas de Gran Canaria, Spania, 35020
- Tilbaketrukket
- Research Site
-
Madrid, Spania, 28041
- Har ikke rekruttert ennå
- Research Site
-
Madrid, Spania, 28040
- Tilbaketrukket
- Research Site
-
Oviedo, Spania, 33011
- Tilbaketrukket
- Research Site
-
Pamplona, Spania, 31008
- Tilbaketrukket
- Research Site
-
Santander, Spania, 39008
- Har ikke rekruttert ennå
- Research Site
-
-
-
-
-
London, Storbritannia, SE5 9RS
- Rekruttering
- Research Site
-
London, Storbritannia, EC1M6BQ
- Rekruttering
- Research Site
-
Newcastle upon Tyne, Storbritannia, NE7 7DN
- Rekruttering
- Research Site
-
Norwich, Storbritannia, NR4 7UY
- Rekruttering
- Research Site
-
Nottingham, Storbritannia, NG5 1PB
- Rekruttering
- Research Site
-
Plymouth, Storbritannia, PL6 8DH
- Rekruttering
- Research Site
-
Southampton, Storbritannia, SO16 6YD
- Tilbaketrukket
- Research Site
-
-
-
-
-
Falun, Sverige, 79182
- Tilbaketrukket
- Research Site
-
Uppsala, Sverige, 75185
- Tilbaketrukket
- Research Site
-
-
-
-
-
Busan, Sør -Korea, 49201
- Rekruttering
- Research Site
-
Busan, Sør -Korea, 49241
- Rekruttering
- Research Site
-
Goyang-si, Sør -Korea, 10408
- Rekruttering
- Research Site
-
Jeonnam, Sør -Korea, 519-763
- Rekruttering
- Research Site
-
Seoul, Sør -Korea, 03080
- Rekruttering
- Research Site
-
Seoul, Sør -Korea, 06351
- Rekruttering
- Research Site
-
Seoul, Sør -Korea, 05505
- Rekruttering
- Research Site
-
Seoul, Sør -Korea, 03722
- Rekruttering
- Research Site
-
Seoul, Sør -Korea, 06591
- Rekruttering
- Research Site
-
-
-
-
-
Changhua, Taiwan, 50006
- Rekruttering
- Research Site
-
Kaohsiung City, Taiwan, 80756
- Rekruttering
- Research Site
-
Kaohsiung City, Taiwan, 833
- Rekruttering
- Research Site
-
Lukang Township, Taiwan, 505029
- Rekruttering
- Research Site
-
Tainan, Taiwan, 704
- Rekruttering
- Research Site
-
Taipei, Taiwan, 106
- Rekruttering
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10330
- Rekruttering
- Research Site
-
Bangkok, Thailand, 10700
- Rekruttering
- Research Site
-
Chiang Mai, Thailand, 50200
- Rekruttering
- Research Site
-
Khon Kaen, Thailand, 40002
- Rekruttering
- Research Site
-
-
-
-
-
Brno, Tsjekkia, 625 00
- Har ikke rekruttert ennå
- Research Site
-
Hradec Králové, Tsjekkia, 500 05
- Har ikke rekruttert ennå
- Research Site
-
Prague, Tsjekkia, 12808
- Har ikke rekruttert ennå
- Research Site
-
-
-
-
-
Ankara, Tyrkia (Türkiye), 6200
- Har ikke rekruttert ennå
- Research Site
-
Ankara, Tyrkia (Türkiye), 6620
- Har ikke rekruttert ennå
- Research Site
-
Istanbul, Tyrkia (Türkiye), 34890
- Har ikke rekruttert ennå
- Research Site
-
Istanbul, Tyrkia (Türkiye), 34010
- Har ikke rekruttert ennå
- Research Site
-
Izmir, Tyrkia (Türkiye), 35340
- Tilbaketrukket
- Research Site
-
-
-
-
-
Berlin, Tyskland, 10967
- Har ikke rekruttert ennå
- Research Site
-
Berlin, Tyskland, 13353
- Har ikke rekruttert ennå
- Research Site
-
Deggendorf, Tyskland, 94469
- Har ikke rekruttert ennå
- Research Site
-
Düsseldorf, Tyskland, 40479
- Har ikke rekruttert ennå
- Research Site
-
Göttingen, Tyskland, 37075
- Har ikke rekruttert ennå
- Research Site
-
Hamburg, Tyskland, 20246
- Har ikke rekruttert ennå
- Research Site
-
Heidelberg, Tyskland, 69120
- Har ikke rekruttert ennå
- Research Site
-
Jena, Tyskland, 07747
- Har ikke rekruttert ennå
- Research Site
-
Karlsruhe, Tyskland, 76133
- Har ikke rekruttert ennå
- Research Site
-
Kiel, Tyskland, 24105
- Har ikke rekruttert ennå
- Research Site
-
Lübeck, Tyskland, 23538
- Har ikke rekruttert ennå
- Research Site
-
Magdeburg, Tyskland, 39120
- Har ikke rekruttert ennå
- Research Site
-
Minden, Tyskland, 32429
- Har ikke rekruttert ennå
- Research Site
-
München, Tyskland, 81377, DE
- Har ikke rekruttert ennå
- Research Site
-
Münster, Tyskland, 48129
- Har ikke rekruttert ennå
- Research Site
-
Regensburgs, Tyskland, 93049
- Har ikke rekruttert ennå
- Research Site
-
Würzburg, Tyskland, 97080
- Har ikke rekruttert ennå
- Research Site
-
-
-
-
-
Budapest, Ungarn, 1122
- Tilbaketrukket
- Research Site
-
Budapest, Ungarn, 1088
- Tilbaketrukket
- Research Site
-
Debrecen, Ungarn, 4032
- Har ikke rekruttert ennå
- Research Site
-
Győr, Ungarn, 9024
- Har ikke rekruttert ennå
- Research Site
-
Kaposvár, Ungarn, 7400
- Har ikke rekruttert ennå
- Research Site
-
Nyíregyháza, Ungarn, 4400
- Tilbaketrukket
- Research Site
-
Pécs, Ungarn, 7624
- Har ikke rekruttert ennå
- Research Site
-
Szeged, Ungarn, 6725
- Har ikke rekruttert ennå
- Research Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participant must be at least 18 years of age, inclusive, at the time of signing the ICF.
- Histologically confirmed diagnosis of classic FL per WHO 2022 classification
- ECOG performance status of 0 to 2
- No prior systemic lymphoma-directed therapy
- Need for systemic treatment meeting at least 1 GELF criteria
- FDG-avid and measurable disease
- Stage II to IV and FLIPI 2-5 [Phase III only]
- Adequate liver, hematological, renal and cardiac function.
The above is a summary, other inclusion criteria details may apply
Exclusion Criteria:
- Follicular large B-cell lymphoma (WHO 2022 classification), formerly Follicular lymphoma Grade 3B (WHO 2016 classification) or suspicion for histologic transformation to high-grade/aggressive lymphoma
- Contra-indication to BR, RCVP, and R-CHOP
- Participants with or history of CNS lymphoma
- History of a clinically relevant CNS medical condition or pathology that required treatment in the preceding year, is currently symptomatic or that which the treating investigator considers to have the potential to interfere with the evaluation of safety
- Presence of >5000 circulating lymphoma cells
- Active or uncontrolled infection (including EBV) requiring systemic therapy and which places participant at unacceptable risk if he/she were to participate in the study. If a participant has a history of COVID-19 within 1 month of C1D1 or contracts COVID while on study treatment, participant must have 2 consecutive negative tests (PCR testing is preferable) performed at least 48 hours apart prior to resuming dosing. All symptoms related to COVID-19 infection should have fully resolved before initiating or resuming treatment
- Known history of hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)
The above is a summary, other exclusion criteria details may apply
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Rituximab, Surovatamig - A
Surovatamig regimen A plus rituximab |
a fully human bispecific monoclonal IgG4 antibody
Andre navn:
|
|
Eksperimentell: Rituximab, Surovatamig - B
Surovatamig regimen B plus rituximab |
a fully human bispecific monoclonal IgG4 antibody
Andre navn:
|
|
Aktiv komparator: Chemoimmunotherapy
Investigator's choice between 3 standard immunochemotherapy regimen (R-CHOP, R-CVP, or B-R followed by rituximab maintenance) |
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Rituximab, Cyclophosphamide, Vincristine and Prednisone Bendamustine, Rituximab |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
SRI Primary: Incidence, nature and severity of AEs and SAEs. Incidence and nature of study drug discontinuations, dose reductions, and dose delays due to AEs
Tidsramme: Up to 10 years
|
Frequency, severity, and relationship to study drug of AEs and SAEs; dose modifications; changes in physical examination and safety procedures. |
Up to 10 years
|
|
SRI Primary: Determination of the recommended Phase III dose (RP3D)
Tidsramme: Up to 1 year
|
The RP3D will be the dose of Surovatamig selected for the Phase 3 part based on safety data compiled during the safety run-in part |
Up to 1 year
|
|
Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy
Tidsramme: Up to 10 years
|
PFS, based on Lugano 2014 Response Criteria, as assessed by BICR. |
Up to 10 years
|
|
Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy
Tidsramme: Up to 10 years
|
ORR at EoI, based on Lugano 2014 Response Criteria, as assessed by BICR. |
Up to 10 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety Run in and Phase 3: ORR at EoI (Investigator assessed)
Tidsramme: Up to 10 years
|
ORR defined as the proportion of participants achieving either a PR or CR at End of Induction based on Lugano 2014 Response Criteria |
Up to 10 years
|
|
Safety Run In and Phase 3: CR Rate
Tidsramme: Up to 10 years
|
CR rate is defined as the proportion of participants achieving a CR at any time as based on Lugano 2014 Response Criteria |
Up to 10 years
|
|
Safety Run In and Phase 3: CR at EoI
Tidsramme: Up to 10 years
|
Proportion of participants achieving CR at End of Induction based on Lugano 2014 Response Criteria |
Up to 10 years
|
|
Safety Run In and Phase 3: DoR
Tidsramme: up to 10 years
|
DoR will be defined from the time of first response until progression based on Lugano 2014 criteria, or death due to any cause |
up to 10 years
|
|
Safety Run In and Phase 3: PFS (Investigator assessed)
Tidsramme: Up to 10 years
|
PFS (Investigator assessed) is defined as time from randomization until disease progression based on Lugano 2014 Response Criteria or death due to any cause |
Up to 10 years
|
|
Safety Run In and Phase 3: OS
Tidsramme: Up to 10 years
|
OS is defined as time until the date of death |
Up to 10 years
|
|
Phase 3: CR rate at 30 months (CR30)
Tidsramme: Up to 30 months
|
Proportion of participants in CR rate at 30 months (CR30) based on Lugano 2014 Response Criteria |
Up to 30 months
|
|
Phase 3: Time to First Subsequent Therapy or Death (TFST)
Tidsramme: Up to 10 Years
|
TFST will be defined as the time from randomization until the start date of first subsequent anti-lymphoma therapy or death due to any cause |
Up to 10 Years
|
|
Phase 3: Time from randomisation to second progression or death (PFS2)
Tidsramme: Up to 10 Years
|
PFS2 will be defined as the time from randomization until the earliest of the progression event, after first subsequent therapy, or death due to any cause |
Up to 10 Years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Chan Cheah, MBBS FRACP FRCPA DMSc, Sir Charles Gairdner Hospital (SCGH)
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- D7401C00001
- 2023 (U.S. NIH-stipend/kontrakt)
- 2023-510098-33-00 (Registeridentifikator: CTIS (EU))
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD-delingstidsramme
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Tilgangskriterier for IPD-deling
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .